中國光大控股有限公司
CHINA EVERBRIGHT LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 165)

PROFIT WARNING

This announcement is made by China Everbright Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 2 February 2021, 11 April 2023, 1 June 2023, 9 September 2024, 11 November 2024, 30 July 2026 and 20 August 2026 (collectively, the "**Announcements**"), and the interim and annual reports published in the corresponding years, which disclosed, among other things, matters pertaining to the litigation against the Group relating to the equity transfer dispute involving Ying Li International Real Estate Limited (the "**Legal Proceedings**"), including the civil judgment made by the Fifth Intermediate People's Court of Chongqing Municipality* (重慶市第五中級人民法院) (the "**Judgment**") and the profit warning in respect of the interim results of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

Following the publication of the Announcement of 20 August 2026 of the Company, having consulted with its legal advisers, the Company has decided to file an appeal with the High People's Court of Chongqing Municipality* (重慶市高級人民法院) against the Judgment within the statutory appeal period, in order to protect the legitimate rights and interests of the Company and its shareholders. The relevant appeal procedures are proceeding in accordance with the law.

Based on the current outcome of the Judgment and taking into consideration the applicable accounting standards, the Company will make a corresponding adjustments in accordance with applicable accounting standards/financial reporting standard in respect of the Legal Proceedings in its interim results for 2026. Affected by such adjustments and financial exposure, it is expected that the Group will record a loss attributable to shareholders of the Company of approximately HK$2.06 billion in its interim results for 2026. The Board emphasizes that the aforementioned accounting adjustments do not materially affect the daily business operations and cash flows of the Group. Currently, the overall operational condition of the Group remains normal. The Company will make further announcement(s) in due course regarding any material development of the Legal Proceedings. The information contained in this announcement is only based on the information currently available to the management, which has not been reviewed or audited by the auditors of the Company.

BOARD CONSIDERATION AND OPINION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The contents of this announcement and the relevant accounting adjustments decision have been approved by the majority of the Board of the Company. Dr. Lin Zhijun, an Independent Non-executive Director of the Company, abstained from voting on the relevant resolution. Dr. Lin stated that based on a legal opinion indicating that the probability of winning the appeal is 50% or above, and that at the time being, there is insufficient justification for making a full provision in respect of the Judgment of the dispute, he abstained from voting on this resolution. Save for Dr. Lin, all other Directors of the Company have no disagreement with the contents of this announcement and the aforementioned accounting adjustments decision.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China Everbright Limited
Wan Kim Ying Kasina
Company Secretary

Hong Kong, 25 August 2026

As at the date of this announcement, the directors of the Company are:

Executive Directors:
Mr. Lin Chun (*Chairman*)
Mr. Pan Jianyun
Mr. An Xuesong
Dr. Su Yang

Independent Non-executive Directors:
Dr. Lin Zhijun
Mr. Law Cheuk Kin Stephen
Mr. Wong Chun Sek Edmund
Dr. Young Danqing Xu

**for identification purposes only*